We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
Trades about 39% below its sector, cheaper than its peers on earnings.
Huons Co., Ltd. operates as a global healthcare company, providing a broad spectrum of medical solutions designed to enhance human health in South Korea and worldwide. Its extensive product line includes a variety of oral solid medications targeting numerous conditions, such as those affecting the circulatory and metabolic systems, pain and inflammation (antipyretic, analgesic, anti-inflammatory), musculoskeletal and digestive health, allergies (antihistamines), respiratory ailments, infections (antibiotics), and products for general well-being, urogenital issues, and various chemotherapeutic applications. The company also manufactures a comprehensive range of injectable pharmaceuticals. These span categories like anesthetics, pain and fever reducers, anti-inflammatory agents, muscle relaxants, antispasmodics, antihistamines, and treatments for circulatory and respiratory system disorders. Further offerings in this format include adrenocortical hormones, enzymes, minerals, solvents, calcium supplements, hemostatics, antidotes, antibiotics, metabolic aids, hyaluronic acid, wellness formulations, anticoagulants, and specialized products for tissue and cell systems. In addition to its pharmaceutical offerings, Huons provides ophthalmic solutions (eye drops), various biological products, and medical devices. Established in 1965 and headquartered in Seongnam, South Korea, the company was initially known as Kwang Myung Pharm before officially changing its name to Huons Co., Ltd. in June 2003.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save 243070.KQ and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.